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Abstract
Background A key issue in the treatment of peripros-
thetic joint infection (PJI) is the correct diagnosis. The
main problem is lack of diagnostic tools able to diagnose a
PJI with high accuracy. Alpha-defensin has been proposed
as a possible solution, but in the current literature, there is a
lack of independent validation.
Questions/purposes We performed a prospective study to
determine (1) what is the sensitivity, specificity, and pos-
itive and the negative predictive values of the alpha-
defensin immunoassay test in diagnosing PJI; and (2)
which clinical features may be responsible for false-posi-
tive and false-negative results?
Methods Preoperative aspiration was performed in all
patients presenting with a painful hip/knee arthroplasty,
including both primary and revision implants. Metallosis,
other inflammatory comorbidities, and previous/concomi-
tant antibiotic therapy were not considered as exclusion
criteria. An inadequate amount of synovial fluid for culture
was an exclusion criterion. A total of 156 patients (65
knees, 91 hips) were included in this prospective study. At
the time of revision, synovial fluid samples were taken to
perform the alpha-defensin assay. During surgical
de´bridement of tissue, samples for cultures and histologic
evaluation were taken, and samples were cultured until
positive or until negative at 14 days. A diagnosis of PJI was
confirmed in 29 patients according to the International
Consensus Group on PJI.
Results The sensitivity of the alpha-defensin immunoas-
say was 97% (95% confidence interval [CI], 92%–99%),
the specificity was 97% (95% CI, 92%–99%), the positive
predictive value was 88% (95% CI, 81%–92%), and the
negative predictive value was 99% (95% CI, 96%–99%).
Among four false-positive patients, two had metallosis and
one had polyethylene wear. The false-negative case pre-
sented with a draining sinus, and intraoperative cultures
were also negative.
Conclusions Alpha-defensin assay appears to be a reli-
able test, but followup evaluation is needed to estimate
longer term performance of the test. The authors believe
that alpha-defensin has demonstrated itself to be suffi-
ciently robust that PJI diagnostic criteria now should
include this test. Future studies are needed to compare the
differences among the diagnostic capability of the available
tests, in particular when metallosis is present, because
metallosis may predispose the test to a false-positive result.
Level of Evidence Level I, diagnostic study.
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Introduction
Periprosthetic joint infection (PJI) is one of the biggest
challenges in orthopaedic surgery today. PJI is reported to
be the cause of failure for 25% [4] of TKA and 15% [3] of
THA. Given the expected increasing incidence and the
economic impact of PJI [18], a strong effort has been
recently made by the international orthopaedic community
to improve the management of this complication of
arthroplasty [5, 20]. A key issue in the treatment of PJI is
making the correct diagnosis as early as possible. Because
the most common symptom of PJI is nonspecific pain,
many tests are used today in an attempt to find the cause of
pain and to differentiate between septic and aseptic revi-
sion surgery with various results [12]. Historically, direct
tissue cultures have been considered the diagnostic stan-
dard; however, these require surgery to be collected and are
neither completely sensitive nor perfectly specific [23]. In
an attempt to guide clinicians in everyday practice, the
Musculoskeletal Infection Society (MSIS) has published a
new diagnostic approach with two existing major or six
minor criteria for diagnosis of PJI [20]. This definition of
PJI was recently revised by the International Consensus
Group on Periprosthetic Joint Infection (Table 1) [5].
According to the PJI Consensus Group, patients should be
considered to have PJI if they meet one of the major cri-
teria or at least three of the minor criteria [5] (Table 2).
Recently, the diagnostic capability of synovial fluid
biomarkers has been highlighted as a possible breakthrough
in this scenario. Promising results have been reported about
alpha-defensin, which is protein naturally released by
neutrophils in response to synovial fluid pathogens [14].
The sensitivity and the specificity of the alpha-defensin
immunoassay test have been reported to be above 96%
[7–10]. Furthermore, it has been demonstrated that a wide
spectrum of organisms triggers the level of alpha-defensin
in the synovial fluid [11]. However, to the best of our
knowledge, with only a couple of exceptions [2, 13], the
research on the alpha-defensin immunoassay test for PJI
diagnosis has been published exclusively by its developers.
Because the sample size of those two studies was quite
limited, there is still lack of independent validation.
Therefore, we performed a prospective study to answer
the following questions: (1) What is the sensitivity,
specificity, positive predictive value, and negative predic-
tive value of the alpha-defensin immunoassay test in
diagnosing a PJI; and (2) which clinical features may be
responsible for false-positive and false-negative alpha-de-
fensin assay results?
Patients and Methods
After approval of the local ethical committee, a prospective
analysis of data collected from the ENDO Klinik,
Table 2. The threshold for the minor diagnostic criteria according to the International Consensus Group
Criterion Acute PJI (\ 90 days) Chronic PJI ([ 90 days)
Erythrocyte sedimentation rate (mm/hr) Not helpful; no threshold was determined 30
C-reactive protein (mg/L) 100 10
Synovia white blood cell count (cells/lL) 10,000 3,000
Synovial polymorphonuclear percentage (%) 90 80
Leukocyte esterase + or ++ + or ++
Histological analysis of tissue [ 5 neutrophils per high-power field in 5 high-power fields (9400) Same as acute
Reprinted from The Journal of Arthroplasty, 29(7), Parvizi J, Gehrke T, Definition of periprosthetic joint infection, Page 1331, Copyright 2014,
with permission from Elsevier; PJI = periprosthetic joint infection.
Table 1. Definition of periprosthetic joint infection (PJI) according to the International Consensus Group
PJI is present when one of the major criteria exists or three of five minor criteria exist
Major criteria Two positive periprosthetic cultures with phenotypically identical organisms, OR
A sinus tract communicating with the joint, OR
Minor criteria (1) Elevated serum C-reactive protein AND erythrocyte sedimentation rate
(2) Elevated synovial fluid white blood cell (WBC) count OR ++change on leukocyte esterase test strip
(3) Elevated synovial fluid polymorphonuclear neutrophil percentage
(4) Positive histological analysis of periprosthetic tissue (5) A single positive culture
Reprinted from The Journal of Arthroplasty, 29(7), Parvizi J, Gehrke T, Definition of periprosthetic joint infection, Page 1331, Copyright 2014,
with permission from Elsevier.
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Hamburg, Germany, was performed in all the patients with
a chronically ([ 90 days) [5] painful knee or hip
arthroplasty who underwent revision surgery from April to
October 2015. Patients with primary arthroplasties and
revision arthroplasties both were considered for inclusion.
No acute revisions (symptoms of less than 90 days’ dura-
tion) [5] were enrolled into the study, because to our
knowledge, alpha-defensin cutoff levels for acute or early
postoperative infection were not known when we began
this study. Informed consent was obtained for each patient
enrolled in the study.
Patients’ histories, clinical evaluations, laboratory exam-
inations including C-reactive protein (CRP), and joint
aspiration fluid were collected preoperatively as routine
diagnostic procedures. Metallosis, other inflammatory
comorbidities, and previous or concomitant antibiotic ther-
apy were not considered as exclusion criteria. An inadequate
amount of synovial fluid for culture was considered an
exclusion criterion. If the amount of fluid was enough,
synovial fluid cell count including granulocyte percentage
and leukocyte esterase (LE) test was performed as well. In
selected patients in whom clinical evaluation and other
minor criteria [5] (Table 2) suggested the presence of
infection, but who had negative fluid cultures, preoperative
tissue biopsies were taken through an open surgical proce-
dure before the planned one-stage revision. At the time of
revision procedure, standardized synovial fluid samples were
taken to perform the alpha-defensin assay test. If no fluid
could be obtained by intraoperative aspiration, the patient
was excluded from the study. After the surgical procedure
and the intraoperative aspiration, 156 patients (90 females,
66 males) presenting with 156 painful total joint arthro-
plasties (65 TKAs, 91 THAs) were included in the study.
Every patient underwent the standard preoperative
diagnostic protocol of ENDO Klinik [15] with blood tests
for CRP and joint aspiration of the painful joint. From the
aspirate standard microbiology cultures, cell count and
granulocyte percentage evaluation were performed. Before
the aspiration, patients were not allowed to take antibiotics
for 2 weeks (antibiotic holiday) and the bacterial samples
were cultured for 14 days in the Microbiology Laboratory
of University Hospital Schleswig-Holstein, Kiel, Germany.
Based on the findings of the preoperative diagnostic tests,
the patients were discussed in the institutional multidisci-
plinary team meeting and arthroplasties were considered as
aseptic or septic according to the diagnostic criteria of the
modified PJI Consensus Group diagnostic protocol [5].
Members of the multidisciplinary team were orthopaedic
surgeons and a microbiology and infectious disease con-
sultant. If a patient had a positive culture, but all other
parameters were negative, the culture result was considered
a false-positive (contaminant), and the revision was
planned as aseptic.
After admission to the ENDO Klinik, all study patients
underwent revision surgery. Patients who were considered
free from PJI based on the criteria evaluable on preopera-
tive aspiration (Table 2) and clinical evaluation were
revised as though there was no infection present with
partial or total exchange of the failed components as
indicated (cup and/or stem exchange after THA or femoral
and/or tibial exchange after TKA). Patients diagnosed as
having PJI underwent a single-stage direct exchange fol-
lowing the ENDO Klinik protocol for PJI if
microorganisms were known in advance or in a two-stage
revision if the bacteriology was not known after preoper-
ative diagnostics [15]. One of the authors (MD) collected
all the aspirates and patient data as part of this prospective
study design. The intraoperative aspiration was performed
after surgical incision, preparation of soft tissues, and
exposure of the capsule without opening the joint (Fig. 1).
A 20-mL syringe and an 18-gauge needle were used to
carefully obtain the synovial fluid avoiding an admixture of
blood. The synovial fluid samples were sent to an inde-
pendent blinded laboratory (Labor Dr. Fenner und
Kollegen, Hamburg, Germany) within 24 hours [9]. The
test kits were provided to the independent laboratory free
of charge by CD Diagnostics (Claymont, DE, USA).
During the surgical de´bridement in both septic and aseptic
revisions, at least three tissue samples for cultures were
taken from different regions of the surgical field according
to a previously described protocol [15]. In the group of
patients suspected as having PJI based on the preoperative
multidisciplinary team meeting, at least two samples for
histological examination were taken as well. Patients were
considered as potentially having a PJI when one of the
major criteria or four of the minor criteria based on the
diagnostic criteria of the PJI Consensus Group [5] are
Fig. 1 Intraoperative aspiration was performed through the capsule
right before capsulotomy, avoiding admixture of blood. The knee is
shown after soft tissue dissection.
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given. This preoperative suspicion was then proven by
intraoperative findings. After 14 days, the results of the
intraoperative cultures and histological findings were col-
lected and these records were added to the database. Both
the microbiologist and the pathologist were blinded to each
patient’s clinical status and to the alpha-defensin level. The
pathologist was not informed about the alpha-defensin
level and the bacterial culture before final histology find-
ing. The microbiologist was not informed about the
histology finding. Metallosis, defined as an intraoperative
macroscopic finding with gray- or black-stained synovial
tissue, which was confirmed by histological investigation
after tissue sampling, was not considered as an exclusion
criterion.
A preoperative biopsy was performed in four patients to
find the causative organism of the suspected PJI. After
preoperative evaluation by the multidisciplinary team, 33
patients were considered to have a PJI. Thirty patients
(91%) underwent a one-stage direct exchange for infection;
in three patients, the first stage of a two-stage revision (9%)
was performed: the implants were removed, thorough
de´bridement was performed, and a customized antibiotic
spacer was inserted. Seven patients (21%) presented with a
draining sinus. The diagnosis of PJI was confirmed by
intraoperative microbiology and histology findings in a
total of 29 patients (Fig. 2). Several microorganisms were
isolated from preoperative and intraoperative cultures
(Table 3). Twenty-seven of them matched the major cri-
teria for PJI according to the PJI Consensus Group
protocol. In two cases the intraoperative culture failed to
show growth and no draining sinus was present; however,
the diagnosis was confirmed by preoperative positive cul-
ture, elevated CRP, and intraoperative positive histology,
matching the PJI Consensus Group minor criteria. In both
cases, a preoperative antibiotic therapy was started as a
result of a high risk of septicemia. Among these 29
patients, the CRP was negative in five (17%) patients.
The remaining 123 patients were diagnosed as not
having PJI and underwent revisions for other indications
(mostly implant loosening). In the series of patients free
form PJI, the CRP was elevated in 10 cases (8%). Coex-
isting metallosis was found in 13 patients (11 without
apparent infection, two apparently with infection). The
diagnosis of metallosis was proven by intraoperative
observation by the surgeon and histological study of tissue
samples. Systemic inflammatory comorbidities were
recorded as well (Table 4).
Statistical Analysis
The results of the alpha-defensin assay were reported as a
semiquantitative signal-to-cutoff ratio of 1.0 as a threshold
for PJI diagnosis. To statistically assess the performance of
the current test, the specificity, sensitivity, positive pre-
dictive value, and negative predictive value were
evaluated.
In particular, specificity indicates the percentage of
subjects without the disease who get a negative test result;
sensitivity indicates the percentage of subjects with the
disease who get a positive test result; positive predictive
value is the probability that the disease is present in case of
a positive test; negative predictive value is the probability
that the disease is not present in case of a negative test. The
95% confidence interval (95% CI) has been calculated for
each of the previous statistical measures.
Table 3. Microorganisms isolated from patients with PJI
Microorganism Number Percentage
Staphylococcus epidermidis 12 41
Enterococcus faecalis 4 14
Staphylococcus hominis 3 10
Streptococcus agalactiae 3 10
Pseudomonas aeruginosa 2 7
Staphylococcus aureus 2 7
Streptococcus dysgalactiae 2 7
Staphylococcus capitis 2 7
Staphylococcus caprae 2 7
Propionibacterium avidum 2 7
Proteus mirabilis 1 3
Staphylococcus lugdunensis 1 3
Stenotrophomonas maltophilia 1 3
PJI = periprosthetic joint infection.
Table 4. Inflammatory disease as a comorbidity factor in the







1 Atopic eczema Aseptic 0.94 0.2
2 Irregular antibodies Aseptic 1.04 \ 0.1
3 Crohn’s disease Aseptic 0.59 \ 0.1
4 Rheumatoid arthritis PJI 26.5 7.1
5 Chronic lymphatic leukemia Aseptic 3.1 \ 0.1
6 Psoriasis Aseptic 9.77 \ 0.1
7 Psoriasis Aseptic 5.88 \ 0.1
8 Rheumatoid arthritis Aseptic 1.67 \ 0.1
9 Lupus erythematodes Aseptic 3.03 \ 0.1
*Nine patients had a relevant systemic disease; alpha-defensin (aD)
was only elevated in one patient with proven PJI; CRP = C-reactive
protein; PJI = periprosthetic joint infection.
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Results
The alpha-defensin assay was positive in 32 joints and
negative in 124 (Fig. 2). When matching these data with
the diagnosis based on the PJI Consensus Group criteria, it
resulted in the alpha-defensin assay being false-positive in
four cases and false-negative in only one case (Fig. 3).
Statistical analysis revealed that the sensitivity of the
alpha-defensin immunoassay was 97% (95% CI, 92%–
99%), the specificity was 97% (95% CI, 92%–99%), the
positive predictive value was 88% (95% CI, 81%–92%),
and the negative predictive value was 99% (95% CI, 96%–
99%).
Among the four patients with a false-positive alpha-
defensin assay, two had a coexisting metallosis and one had
severe polyethylene wear with osteolysis (Fig. 4). In one
patient no particular clinical feature was noticed. The two
cases with metallosis had a negative CRP, whereas the
patient with polyethylene wear had a CRP of 15 mg/L. Cell
count and LE tests were not available for any of these three
Fig. 3 Synovial fluid alpha-de-
fensin values (logarithmic scale)
for aseptic and PJI patients are
shown separately. The line indi-
cates the alpha-defensin
diagnostic threshold of 1.0 (sig-
nal-to-cutoff ratio [S/CO]). The
five white dots represent the
misdiagnosed patients, being
false-negative (in the PJI group)
or false-positive (in the aseptic
group).
Fig. 2 Workflow describing the
features of the patients included
in the study. Reproduced with
permission from Silvia Bassini.
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patients. The false-negative case presented with a draining
sinus; the intraoperative cultures were negative but the
CRP was 15 mg/L and the granulocyte percentage was
80%.
Discussion
Although several strategies are available today for surgical
management of PJI, the diagnosis remains challenging as a
result of the lack of diagnostic tools able to diagnose PJI
with reliable specificity and sensitivity [20]. Recently,
synovial fluid biomarkers such as alpha-defensin have been
proposed as a possible solution in this complex scenario
with very promising results [8–11]. In the current series,
the alpha-defensin immunoassay has shown both sensitiv-
ity and specificity as high as 97%. Furthermore, the
positive and negative predictive values were, respectively,
88% and 99%, demonstrating outstanding performance of
alpha-defensin if the result is negative; in other words, if
the alpha-defensin test is negative, it is quite likely that the
pain in the joint after THA or TKA is not caused by PJI. If
the result is positive, the likelihood of PJI is very high, but
other reasons for elevated alpha-defensin level should be
considered and excluded.
The authors noted some limitations of the current study.
First, the sample size was quite small compared with other
studies on PJI diagnosis [1, 16, 21]. However, when
looking at the available research, this was the largest sin-
gle-center study evaluating alpha-defensin assay.
Furthermore, this was the only single-center series of
which we are aware that included patients with metallosis,
wear, and inflammatory comorbidities. Second, all clinical
data exploitable for the PJI Consensus Group criteria were
not available for all patients, but this is a common problem
in clinical practice because the aspiration fluid is often not
adequate in quantity and/or quality to perform all required
tests. The lack of some tests combined with the size of the
series did not allow for statistical comparison of diagnostic
capability between the alpha-defensin assay and other tests.
However, for all patients who received a positive alpha-
defensin test, there was a sufficient amount of data to
confirm or rule out the infection according to the PJI
Consensus Group criteria. Third, the synovial fluid samples
used to perform the alpha-defensin assay test were col-
lected intraoperatively after surgical incision and
dissection. This was an ideal condition in which the aspi-
ration was performed directly through the capsule but not
reproducible in everyday clinical practice, like in the out-
patient clinic. Fourth, erythrocyte sedimentation rate (ESR)
was not available for any patient because in our institution,
it is not routinely performed in patients undergoing workup
for PJI. However, it has been proved that ESR is not
specific for PJI with a reported specificity of 68% to 87%
[1, 6, 16, 17, 19, 22]. Finally, our results should be con-
sidered a best-case estimate of the test’s performance,
because there was no extended surveillance here, and so it
remains possible that some of the patients diagnosed as
being without PJI may indeed have an indolent infection
and present later. Future studies with longer followup
clearly are called for to address this issue.
The results of the current article are consistent with the
limited available research on this topic. First, Deirmengian
et al. [10] have tested 16 possible synovial biomarkers of
Fig. 4 Preoperative AP radio-
graph of a patient with false-
positive alpha-defensin value
reveals polyethylene wear and
osteolysis of the proximal femur
at his right THA.
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95 patients (66 patients with aseptic complications, 29
patients with PJI) and reported that five biomarkers,
including alpha-defensin, provided a diagnosis that mat-
ched with the MSIS criteria for the whole series. In this
study, patients presenting with adverse reactions to metal
debris were excluded, whereas no inflammatory comor-
bidity was considered as exclusion criteria. Bingham et al.
[2] have reported even better results for the alpha-defensin
assay alone in 61 aspirations (19 septic, 42 aseptic aspi-
rates). In their series, the sensitivity was 100% (95% CI,
79%–100%) and the specificity was 95% (95% CI, 83%–
99%). Patients with a concomitant autoimmune disease
were excluded and other comorbidities were not men-
tioned. However, they failed to show any significant
difference in ruling out PJI except with respect to ESR; this
latter test was not performed in the current study. More
recently, Frangiamore et al. [13] reported about a mixed
series combining single-stage revisions with reimplanta-
tions at two-stage revision. The sensitivity and the
specificity for the single-stage group were 100% (95% CI,
86%–100%) and 95% (95% CI, 90%–100%), respectively.
Interestingly, they noticed that the performance of the
alpha-defensin assay was poorer in the second-stage group,
especially concerning the sensitivity that went down to
67% (95% CI, 12%–95%). However, the authors noticed
the sample size was too small to allow for appropriate
evaluation. Another report by Deirmengian et al. [9],
including patients with coexisting metallosis and inflam-
matory comorbidities, gained results similar to the current
paper. In a series of 149 patients (112 patients with an
aseptic complication, 37 patients with PJI), the specificity
and the sensitivity were reported to be 96% (95% CI, 90%–
99%) and 97% (95% CI, 86%–99.6%), respectively.
Interestingly, it was noted that including the value of
synovial fluid CRP in diagnostic algorithm, the overall
specificity increased to 100% (95% CI, 96.7%–100%).
Another finding of the current study is that among the
four reported false-positive arthroplasties, two patients had
a coexisting metallosis, but alpha-defensin was not influ-
enced by any systemic inflammatory disease (Table 4).
Deirmengian et al. [9] reported on three hips revised for
metallosis out of five false-positive joints. These data
highlight that metallosis could be a misleading factor in
reading alpha-defensin assay results. However, the alpha-
defensin value was not elevated in most of the patients
diagnosed as being without infection with a coexisting
metallosis in either series. The other two papers reporting
misclassified patients did exclude patients with a metallo-
sis. Bingham et al. [2] recorded two patients with false-
positive results. In those patients, other markers of
inflammation such as CRP, cell count, and ESR were ele-
vated as well. They theorized that aseptic inflammation
might be responsible for elevated alpha-defensin levels.
Frangiamore et al. [13] observed two false-positive results;
however, one patient was undergoing a second-stage revi-
sion and as the authors recognized, this biomarker assay is
designed only for the first operation of a two-stage
exchange for infection or a single-stage revision. A possi-
ble interpretation of these data could be that in case of
elevated synovial alpha-defensin levels and less than three
minor criteria according to the PJI Consensus Group, the
presence of possible metal debris should be considered.
Like in the current series, Deirmengian et al. [9] also
reported only one false-negative. In both series, the cul-
tures were negative but the diagnosis was done by
matching other PJI Consensus Group criteria. In the series
of Frangiamore et al. [13], there was one false-negative
patient as well; this subject had a positive culture but it was
considered contamination.
In conclusion, the findings of this study suggest that the
alpha-defensin assay has a role to play in the complex
scenario of PJI diagnosis. However, like with all the other
available tests, it is not the perfect diagnostic tool with
100% specificity and sensitivity, but this independent
confirmation of the performance of alpha-defensin suggests
that it could be integrated among the existing PJI diag-
nostic criteria. However, our results should be considered a
best-case estimate of the test’s performance, because there
was no followup evaluation. Therefore, it remains possible
that some of the patients diagnosed as being without PJI
may indeed have a chronic, indolent infection and present
later. Future studies with larger series are needed to sta-
tistically compare the difference among the diagnostic
capabilities of the available tests. Particular effort is needed
for those patients presenting with a coexisting metallosis,
which may predispose the test to a false-positive result.
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